Slingshot members are tracking this event:

Pfizer Announces FDA Approval of XELJANZ XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
PFE Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 24, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Xeljanz Xr, Tofacitinib Citrate, Jak Inhibitor Treatment, Rheumatoid Arthritis